



Contact:

David Waldman or Justyna Gudaszevska
Crescendo Communications Europe Sp. z o.o.
Email: mmd@crescendo-ir.com
Tel: + 48 71 79 11 551

**Milestone Medical Announces Epidural Instrument Trials
at Second Clinical Site in the United States**

LIVINGSTON, NJ, March 10, 2015 -- Milestone Medical Inc. (WAR: MMD) today announced the commencement of clinical trials for its epidural instrument at a second clinical site in the United States. This follows the company's recent announcement last week that it had started its pivotal clinical trial for the epidural instrument in the United States.

Leonard Osser, Chief Executive Officer of Milestone Medical, stated, "We are pleased to announce the second site for our clinical trials in the United States. This Pain Institute is led by one of the premiere anesthesiologists and interventional pain management specialists in the U.S. He is also a member of multiple national pain societies and has lectured extensively throughout the U.S. We appreciate the interest we have received from a variety of leading pain management clinics and key opinion leaders to participate in our pivotal clinical trial."

About Milestone Medical Inc.

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval in the U.S. and has recently received CE approval for both instruments in the European Union. For more information please visit www.medicalmilestone.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.